aflibercept-ayyh 2 MG per 0.05 ML Prefilled Syringe

RxCUI: 2696260
RxNorm name: aflibercept-ayyh 2 MG per 0.05 ML Prefilled Syringe
Display name: aflibercept-ayyh 2 MG per 0.05 ML Prefilled Syringe
Full name: aflibercept-ayyh 2 MG per 0.05 ML Prefilled Syringe
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:20

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761298	Pavblu	aflibercept-ayyh	351(k) Biosimilar	Rx	2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
PAVBLU	AFLIBERCEPT-AYYH	Amgen, Inc	c61062f3-80ec-4a20-8c28-46e468592a06	2026-05-10	Warnings, Adverse reactions	Exact identifier rxcui: 2696260

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
c61062f3-80ec-4a20-8c28-46e468592a06	aflibercept-ayyh 2 MG per 0.05 ML Prefilled Syringe	SY	9	These highlights do not include all the information needed to use PAVBLU safely and effectively. See full prescribing information for PAVBLU. PAVBLU ® (aflibercept-ayyh) injection, for intravitreal use Initial U.S. Approval: 2024 PAVBLU (aflibercept-ayyh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee	20260510
c61062f3-80ec-4a20-8c28-46e468592a06	aflibercept-ayyh 2 MG in 0.05 ML Prefilled Syringe	PSN	9	These highlights do not include all the information needed to use PAVBLU safely and effectively. See full prescribing information for PAVBLU. PAVBLU ® (aflibercept-ayyh) injection, for intravitreal use Initial U.S. Approval: 2024 PAVBLU (aflibercept-ayyh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee	20260510
c61062f3-80ec-4a20-8c28-46e468592a06	0.05 ML aflibercept-ayyh 40 MG/ML Prefilled Syringe	SCD	9	These highlights do not include all the information needed to use PAVBLU safely and effectively. See full prescribing information for PAVBLU. PAVBLU ® (aflibercept-ayyh) injection, for intravitreal use Initial U.S. Approval: 2024 PAVBLU (aflibercept-ayyh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee	20260510